Cantor Fitzgerald Reiterates Cidara Therapeutics (CDTX) at Overweight, Believes the Street Underappreciates Company's Sales Potential, Sees Upward Earnings Revisions
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $5.00 price target on Cidara Therapeutics (NASDAQ: CDTX), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
